Melior Discovery Selected as Preclinical CRO to Support Linnaeus Therapeutics' ARPA-H PROSPR Program
Melior Discovery will conduct preclinical in vivo pharmacology studies supporting Linnaeus' ARPA-H PROSPR-funded development of LNS8801 for healthspan preservation EXTON, Pa., July 21, 2026 /PRNewswire-PRWeb/ -- Melior Discovery, Inc. (Melior), a dedicated in vivo pharmacology contract...
Melior Discovery will conduct preclinical in vivo pharmacology studies supporting Linnaeus' ARPA-H PROSPR-funded development of LNS8801 for healthspan preservation EXTON, Pa., July 21, 2026 /PRNewswire-PRWeb/ -- Melior Discovery, Inc. (Melior), a dedicated in vivo pharmacology contract...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.